Javelin Pharmaceuticals (JAV -14.5%) falls as Hospira (HSP +0.7%) extends its tender offer of...


Javelin Pharmaceuticals (JAV -14.5%) falls as Hospira (HSP +0.7%) extends its tender offer of $2.20/share for a second time due to concerns about the state of Javelin's business. Javelin files suit to compel Hospira to follow through on the merger agreement.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs